[Translation] Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of CG-7321 as a single agent or in combination therapy in subjects with advanced solid tumors
评价 CG-7321用于晚期实体瘤受试者的安全性、耐受性,确定CG-7321的最大耐受剂量(MTD)和临床II期推荐剂量(RP2D);评价 CG-7321用于晚期实体瘤受试者的药代动力学特征,初步评价CG-7321用于晚期实体瘤受试者的抗肿瘤活性。
[Translation] To evaluate the safety and tolerability of CG-7321 in subjects with advanced solid tumors, determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of CG-7321; to evaluate the pharmacokinetic characteristics of CG-7321 in subjects with advanced solid tumors, and preliminarily evaluate the anti-tumor activity of CG-7321 in subjects with advanced solid tumors.